Literature DB >> 31790067

Validation of a Head-mounted Virtual Reality Visual Field Screening Device.

Lukas Mees1, Swati Upadhyaya2, Pavan Kumar2, Sandal Kotawala3, Shankar Haran3,4, Shruthi Rajasekar3,4, David S Friedman1,5, Rengaraj Venkatesh2.   

Abstract

PRéCIS:: The C3 fields analyzer (CFA) is a moderately reliable perimeter preferred by patients to standard perimetry. While it does not approximate the gold standard, it was sensitive and specific for clinically defined glaucoma (area under the receiving operator characteristic curve=0.77 to 0.86).
PURPOSE: Testing the visual field is a vital sign for diagnosing and managing glaucoma. The current gold standard, the Humphrey visual field analyzer (HFA), is large, expensive and can be uncomfortable for some patients. The current study investigated the CFA, a virtual reality head-mounted visual field testing device, as a possible subjective field test for glaucoma screening and eventually glaucoma monitoring. PATIENTS AND METHODS: The CFA presented stimuli in the same 54 positions as the HFA 24-2 SITA Standard test using a suprathreshold algorithm approximating an 18 dB deficit. A total of 157 patients (both controls and glaucoma patients) at the Aravind Eye Hospital, Pondicherry, India, were tested with both devices.
RESULTS: The number of stimuli missed on the CFA correlated with HFA mean deviation (r=0.62, P<0.001), and with pattern standard deviation (r=0.36, P<0.001). The area under the receiving operator characteristic curve was 0.77±0.06 for mild glaucoma (HFA mean deviation ≥-6 dB) and 0.86±0.04 for moderate-advanced glaucoma (HFA mean deviation <-6 dB). Patients with an 18 dB or worse deficit at a point in the visual field on the HFA failed to see the CFA stimulus at the same position 38% of the time.
CONCLUSIONS: While the CFA did not reliably identify deficits that matched the HFA, it was moderately effective at identifying glaucoma subjects. Further refinements to the device will be required to improve point by point testing performance and screening performance.

Entities:  

Mesh:

Year:  2020        PMID: 31790067     DOI: 10.1097/IJG.0000000000001415

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  8 in total

1.  Home perimetry. Is possible?

Authors:  F J Muñoz-Negrete; J Moreno-Montañés; G Rebolleda
Journal:  Arch Soc Esp Oftalmol (Engl Ed)       Date:  2021-05-15

2.  Comparison of the visual field test of Glaufield Lite with Humphrey Field Analyser.

Authors:  Geeta Behera; Shradha Vijay Waghmare; Amala Ramasamy
Journal:  Int Ophthalmol       Date:  2022-08-10       Impact factor: 2.029

3.  A Virtual Reality Orientation and Mobility Test for Inherited Retinal Degenerations: Testing a Proof-of-Concept After Gene Therapy.

Authors:  Tomas S Aleman; Alexander J Miller; Katherine H Maguire; Elena M Aleman; Leona W Serrano; Keli B O'Connor; Emma C Bedoukian; Bart P Leroy; Albert M Maguire; Jean Bennett
Journal:  Clin Ophthalmol       Date:  2021-03-02

4.  Eye-Tracking for Clinical Ophthalmology with Virtual Reality (VR): A Case Study of the HTC Vive Pro Eye's Usability.

Authors:  Alexandra Sipatchin; Siegfried Wahl; Katharina Rifai
Journal:  Healthcare (Basel)       Date:  2021-02-09

5.  New Strategies for Automated Perimetry: Historical Perspective and Future Innovations.

Authors:  Sylvia L Groth
Journal:  J Curr Glaucoma Pract       Date:  2021 Sep-Dec

6.  Diagnostic Performance of the PalmScan VF2000 Virtual Reality Visual Field Analyzer for Identification and Classification of Glaucoma.

Authors:  Vijay Shetty; Prachi Sankhe; Suhas S Haldipurkar; Tanvi Haldipurkar; Rita Dhamankar; Priyanka Kashelkar; Dhruven Shah; Paresh Mhatre; Maninder Singh Setia
Journal:  J Ophthalmic Vis Res       Date:  2022-01-21

Review 7.  Virtual Reality and Augmented Reality in Ophthalmology: A Contemporary Prospective.

Authors:  Mina Iskander; Titilola Ogunsola; Rithambara Ramachandran; Richard McGowan; Lama A Al-Aswad
Journal:  Asia Pac J Ophthalmol (Phila)       Date:  2021 May-Jun 01

Review 8.  The Future Is Now: Incorporating Telemedicine into Glaucoma Care.

Authors:  Monica K Ertel; Malik Y Kahook; Cara E Capitena Young
Journal:  Curr Ophthalmol Rep       Date:  2021-07-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.